Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane
The objective of the present clinical investigation is to determine whether hormonal therapy given preoperatively is able to reduce tumor size to an extent that facilitates breast-conserving procedures.
Breast Cancer
PROCEDURE: rate of remission
rate of remission
Toxicity (WHO-grading)|rate of mastectomy|response of tumor subject to HER2-status|collection of disease free survival and overall survival
This open, prospective multicenter Phase II pilot trial investigates the efficacy of exemestane, 25 mg once daily over 4 months, in postmenopausal women with primary breast cancer, measured in terms of clinical response